Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$1.26 -2.3%	$1.22	$0.46 ▼ $7.49	$6.90M	-0.1	10.27 million shs	57,049 shs
PEPG PepGen	$1.07 -10.1%	$1.34	$0.88 ▼ $10.15	$38.94M	1.19	191,891 shs	296,875 shs
PHGE BiomX	$0.48 -35.5%	$0.45	$0.34 ▼ $2.40	$15.55M	1.42	347,190 shs	53,300 shs
RNXT RenovoRx	$1.14 -5.0%	$1.31	$0.75 ▼ $1.69	$43.89M	1.26	105,607 shs	194,041 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	-2.33%	-8.03%	+40.00%	+46.36%	-54.01%
PEPG PepGen	-10.08%	-18.94%	-9.32%	-28.67%	-87.95%
PHGE BiomX	-19.15%	+21.37%	+13.57%	-16.17%	-72.74%
RNXT RenovoRx	-5.00%	-5.79%	-13.31%	+7.55%	+2.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	1.2642 of 5 stars	0.0	5.0	1.5	1.7	0.6
PEPG PepGen	2.6739 of 5 stars	3.2	2.0	2.3	2.5	1.3
PHGE BiomX	2.0104 of 5 stars	3.5	0.0	1.1	0.8	1.3
RNXT RenovoRx	2.5026 of 5 stars	3.5	5.0	1.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
PEPG PepGen	2.33	Hold	$7.67	616.51% Upside
PHGE BiomX	3.00	Buy	$21.00	4,302.52% Upside
RNXT RenovoRx	3.00	Buy	$7.25	535.96% Upside

Current Analyst Ratings Breakdown

Latest PHGE, APM, PEPG, and RNXT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/16/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	15.68	N/A	N/A	$2.20 per share	0.57
PEPG PepGen	N/A	N/A	N/A	N/A	$3.64 per share	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A
RNXT RenovoRx	$40K	1,042.25	N/A	N/A	$0.19 per share	6.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	-$89.98M	-$3.13	N/A	N/A	N/A	N/A	-83.58%	-64.82%	8/14/2025 (Estimated)
PHGE BiomX	-$28.32M	-$0.85	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	N/A	-119.58%	-88.01%	8/14/2025 (Estimated)

Latest PHGE, APM, PEPG, and RNXT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PEPG PepGen	-$0.8150	-$0.70	+$0.1150	-$0.70	N/A	N/A
8/14/2025	Q2 2025	RNXT RenovoRx	-$0.08	N/A	N/A	N/A	$0.25 million	N/A
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
PEPG PepGen	N/A	4.95	4.95
PHGE BiomX	0.51	2.84	2.84
RNXT RenovoRx	N/A	9.07	9.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
PEPG PepGen	58.01%
PHGE BiomX	40.57%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
PEPG PepGen	5.20%
PHGE BiomX	1.17%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
PEPG PepGen	30	32.72 million	31.02 million	Not Optionable
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable

PHGE, APM, PEPG, and RNXT Headlines

Recent News About These Companies

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

August 6 at 8:30 AM | globenewswire.com

RenovoRx (NASDAQ:RNXT) Stock Rating Lowered by Wall Street Zen

August 4, 2025 | americanbankingnews.com

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

July 28, 2025 | finance.yahoo.com

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

July 14, 2025 | businesswire.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

Le BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisions

May 15, 2025 | fr.investing.com

Transcription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentes

May 15, 2025 | fr.investing.com

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025 | businesswire.com

Earnings Preview For RenovoRx

May 14, 2025 | benzinga.com

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025 | finance.yahoo.com

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025 | finance.yahoo.com

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRx

April 30, 2025 | zonebourse.comZ

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-Pac

April 29, 2025 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, APM, PEPG, and RNXT Company Descriptions

Aptorum Group NASDAQ:APM

$1.26 -0.03 (-2.33%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.25 -0.01 (-0.79%)

As of 08/8/2025 06:50 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

PepGen NASDAQ:PEPG

$1.07 -0.12 (-10.08%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.08 +0.01 (+0.93%)

As of 08/8/2025 07:56 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

BiomX NYSEMKT:PHGE

$0.48 -0.26 (-35.45%)

Closing price 08/8/2025 03:58 PM Eastern

Extended Trading

$0.46 -0.02 (-3.98%)

As of 08/8/2025 08:00 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

RenovoRx NASDAQ:RNXT

$1.14 -0.06 (-5.00%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.14 0.00 (0.00%)

As of 08/8/2025 04:10 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time